We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Genome Engineering Technique Eases Gene Repair in Human Pluripotent Stem Cells

By LabMedica International staff writers
Posted on 29 Aug 2013
An RNA-guided, DNA-cleaving interference pathway from bacteria [the type II clustered, regularly interspaced, short palindromic repeats (CRISPR)-CRISPR-associated (Cas) pathway] has been adapted for use in eukaryotic cells, greatly facilitating genome editing.

The CRISPR/Cas (CRISPR associated) system is a new genome-engineering technology recently developed from prokaryotes' adaptive immune response systems. More...
The CRISPR system uses a short, noncoding RNA (crRNA) to target a human codon-optimized Cas9 nuclease to complementary (protospacer) sequences in the host genome. These sequences or arrays are composed of direct repeats that are separated by similarly sized nonrepetitive spacers. CRISPR arrays, together with a group of associated proteins, confer resistance to phages, possibly by an RNA-interference-like mechanism.

Investigators at the University of Wisconsin (Madison USA) and their colleagues at Northwestern University (Evanston, IL, USA) used a CRISPR-Cas system identified in the bacterium Neisseria meningitidis, which is distinct from the commonly used Streptococcus pyogenes system, to demonstrate efficient genome engineering in human pluripotent stem cells (hPSCs).

Heretofore, only two CRISPR-Cas systems (from S. pyogenes and S. thermophilus), each with their own distinct targeting requirements and limitations, had been developed for genome editing. In addition, only limited information existed regarding homology-directed repair (HDR)-mediated gene targeting using long donor DNA templates in hPSCs with these systems.

The investigators wrote in the August 12, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that by employing a distinct CRISPR-Cas system from N. meningitidis, they were able to demonstrate efficient targeting of an endogenous gene in three hPSC lines using HDR. The Cas9 RNA-guided endonuclease from N. meningitidis (NmCas9) recognized a protospacer adjacent motif (PAM) different from those recognized by Cas9 proteins from S. pyogenes and S. thermophilus (SpCas9 and StCas9, respectively). Similar to SpCas9, NmCas9 was able to use a single-guide RNA (sgRNA) to direct its activity. Because of its distinct protospacer adjacent motif, the N. meningitidis CRISPR-Cas machinery increased the sequence contexts amenable to RNA-directed genome editing.

“Human pluripotent stem cells can proliferate indefinitely and they give rise to virtually all human cell types, making them invaluable for regenerative medicine, drug screening, and biomedical research,” said senior author Dr. James A. Thomson, professor of embryonic stem cell biology at the University of Wisconsin. “Our collaboration with the Northwestern team has taken us further toward realizing the full potential of these cells because we can now manipulate their genomes in a precise, efficient manner. With this system, there is the potential to repair any genetic defect, including those responsible for some forms of breast cancer, Parkinson’s, and other diseases.”

Related Links:
University of Wisconsin
Northwestern University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.